Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation

Blood

Volumn 113, Issue 22, 2009, Pages 5444-5455

  Hoggatt, Jonathan ^a   Singh, Pratibha ^a   Sampath, Janardhan ^a   Pelus, Louis M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; SURVIVIN; CXCR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL HOMING; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; CELL MOTION; DRUG EFFECT; EVALUATION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; PHYSIOLOGY; STEM CELL MOBILIZATION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DINOPROSTONE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTORS, CXCR4; RECEPTORS, PROSTAGLANDIN E; TRANSPLANTATION CONDITIONING;

EID: 67049134758     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-201335     Document Type: Article

References (55)

1. Miller SB. Prostaglandins in health and disease: an overview. Semin Arthritis Rheum. 2006;36:37-49.
2. Pelus LM, Broxmeyer HE, Kurland JI, Moore MA. Regulation of macrophage and granulocyte proliferation: specificities of prostaglandin E and lactoferrin. J Exp Med. 1979;150:277-292.
3. Pelus LM, Broxmeyer HE, Moore MA. Regulation of human myelopoiesis by prostaglandin E and lactoferrin. Cell Tissue Kinet. 1981;14:515-526.
4. Gentile P, Byer D, Pelus LM. In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. Blood. 1983;62:1100-1107.
5. Lu L, Pelus LM, Broxmeyer HE. Modulation of the expression of HLA-DR (Ia) antigens and the proliferation of human erythroid (BFU-E) and multipotential (CFU-GEMM) progenitor cells by prostaglandin E. Exp Hematol. 1984;12:741-748. (Pubitemid 14014332)
6. Lu L, Pelus LM, Piacibello W, et al. Prostaglandin E acts at two levels to enhance colony formation in vitro by erythroid (BFU-E) progenitor cells. Exp Hematol. 1987;15:765-771. (Pubitemid 17151449)
7. Feher I, Gidali J. Prostaglandin E2 as stimulator of haemopoietic stem cell proliferation. Nature. 1974;247:550-551.
8. Verma DS, Spitzer G, Zander AR, McCredie KB, Dicke KA. Prostaglandin E1-mediated augmentation of human granulocyte-macrophage progenitor cell growth in vitro. Leuk Res. 1981;5:65-71. (Pubitemid 11154745)
9. Pelus LM. Association between colony forming units-granulocyte macrophage expression of Ialike (HLA-DR) antigen and control of granulocyte and macrophage production: a new role for prostaglandin E. J Clin Invest. 1982;70:568-578.
10. North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447:1007-1011.
11. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106:1901-1910.
12. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091-2100.
13. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood. 2002;100:2463-2471.
14. Harrison DE. Competitive repopulation: a new assay for long-term stem cell functional capacity. Blood. 1980;55:77-81.
15. Fukuda S, Pelus LM. Internal tandem duplication of Flt3 modulates chemotaxis and survival of hematopoietic cells by SDF1alpha but negatively regulates marrow homing in vivo. Exp Hematol. 2006;34:1041-1051. (Pubitemid 44080382)
16. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
18. Harizi H, Grosset C, Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol. 2003;73:756-763.
19. Panzer U, Uguccioni M. Prostaglandin E2 modulates the functional responsiveness of human monocytes to chemokines. Eur J Immunol. 2004;34:3682-3689. (Pubitemid 40012186)
20. Villablanca EJ, Pistocchi A, Court FA, et al. Abrogation of prostaglandin E2/EP4 signaling impairs the development of rag1+ lymphoid precursors in the thymus of zebrafish embryos. J Immunol. 2007;179:357-364. (Pubitemid 46986552)
21. Chen J, Ellison FM, Keyvanfar K, et al. Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol. 2008;36:1236-1243.
22. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121. (Pubitemid 40884400)
23. Ramshaw HS, Crittenden RB, Dooner M, et al. High levels of engraftment with a single infusion of bone marrow cells into normal unprepared mice. Biol Blood Marrow Transplant. 1995;1:74-80.
24. Gandy KL, Domen J, Aguila H, Weissman IL. CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11:579-590.
25. Okada S, Nakauchi H, Nagayoshi K, et al. In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood. 1992;80:3044-3050.
26. Dick JE, Sirard C, Pflumio F, Lapidot T. Murine models of normal and neoplastic human haematopoiesis. Cancer Surv. 1992;15:161-181.
27. Jetmore A, Plett PA, Tong X, et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. Blood. 2002;99:1585-1593. (Pubitemid 34533030)
28. Goichberg P, Kalinkovich A, Borodovsky N, et al. cAMP-induced PKCzeta activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. Blood. 2006;107:870-879. (Pubitemid 43156281)
29. Salcedo R, Zhang X, Young HA, et al. Angiogenic effects of prostaglandin E2 are mediated by upregulation of CXCR4 on human microvascular endothelial cells. Blood. 2003;102:1966-1977. (Pubitemid 37122368)
30. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998;91:100-110.
31. Hatse S, Princen K, Bridger G, De CE, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527:255-262. (Pubitemid 35253875)
32. Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305:1000-1003. (Pubitemid 39071774)
33. Fukuda S, Bian H, King AG, Pelus LM. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood. 2007;110:860-869. (Pubitemid 47267422)
34. Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol. 1992;20:391-394.
35. George RJ, Sturmoski MA, Anant S, Houchen CW. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat. 2007;83:112-120. (Pubitemid 46149405)
36. Fernandez-Martinez A, Molla B, Mayoral R, et al. Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells. Biochem J. 2006;398:371-380. (Pubitemid 44453381)
37. Negrotto S, Pacienza N, D'Atri LP, et al. Activation of cyclic AMP pathway prevents CD34(+) cell apoptosis. Exp Hematol. 2006;34:1420-1428. (Pubitemid 44374835)
38. Fukuda S, Pelus LM. Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle. 2002;1:322-326.
39. Baratelli F, Krysan K, Heuze-Vourc'h N, et al. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol. 2005;78:555-564. (Pubitemid 41061327)
40. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 2004;18:206-208.
41. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320. (Pubitemid 28551107)
42. Fleming HE, Janzen V, Lo CC, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008;2:274-283. (Pubitemid 351298592)
43. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003;74:143-153.
44. Muller-Sieburg CE, Sieburg HB. Clonal diversity of the stem cell compartment. Curr Opin Hematol. 2006;13:243-248.
45. Khan NI, Bendall LJ. Role of WNT signaling in normal and malignant hematopoiesis. Histol Histopathol. 2006;21:761-774. (Pubitemid 44082718)
46. Wang D, Mann JR, DuBois RN. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle. 2004;3:1512-1515. (Pubitemid 40521402)
47. Leung CG, Xu Y, Mularski B, et al. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med. 2007;204:1603-1611. (Pubitemid 47048027)
48. Fukuda S, Singh P, Conway EM, Yamaguchi S, Pelus LM. Survivin regulates aberrant proliferation of hematopoietic progenitor cells with self-renewal capability and development of acute leukemia induced by internal-tandem- duplication of Flt3. Blood. 2007;110:599a.
49. Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood. 2004;103:120-127. (Pubitemid 38029926)
50. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000;287:1804-1808. (Pubitemid 30143963)
51. Janzen V, Fleming HE, Riedt T, et al. Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3. Cell Stem Cell. 2008;2:584-594. (Pubitemid 351751901)
52. Peng XH, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281:25903-25914. (Pubitemid 44401796)
53. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425:307-311. (Pubitemid 37158407)
54. Piccoli C, D'Aprile A, Ripoli M, et al. The hypoxia-inducible factor is stabilized in circulating hematopoietic stem cells under normoxic conditions. FEBS Lett. 2007;581:3111-3119. (Pubitemid 46899058)
55. Lorenz M, Slaughter HS, Wescott DM, et al. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol. 1999;27:1494-1502. (Pubitemid 29458423)